8A-PDHQ
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
131556-11-1  N |
| PubChem (CID) | 131397 |
| ChemSpider |
116144  Y |
| Chemical and physical data | |
| Formula | C15H21N |
| Molar mass | 215.3339 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| NY (what is this?) (verify) | |
8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.[2][3]
References
- ↑ US Patent 3035059
- ↑ Chen C; Kozikowski AP; Wood PL; Reynolds IJ; Ball RG; Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.
- ↑ Elhallaoui M; Laguerre M; Carpy A; Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600.
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (blockers) |
| ||||||||||||||||||||||||||||||||||||||||||
| Enzyme (inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||
See also: GABAergics • GHBergics • Glycinergics | |||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the 5/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.